<?xml version="1.0" encoding="UTF-8"?>
<ref id="R8">
 <label>8</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <string-name>
    <surname>Fizazi</surname>
    <given-names>K</given-names>
   </string-name>, 
   <string-name>
    <surname>Tran</surname>
    <given-names>N</given-names>
   </string-name>, 
   <string-name>
    <surname>Fein</surname>
    <given-names>L</given-names>
   </string-name>, 
   <etal>et al</etal>
  </person-group>. 
  <article-title>Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer</article-title>. 
  <source>N Engl J Med</source>
  <year>2017</year>;
  <volume>377</volume>:
  <fpage>352</fpage>â€“
  <lpage>60</lpage>. 
  <pub-id pub-id-type="doi">10.1056/NEJMoa1704174</pub-id>
  <?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/28578607?>
  <pub-id pub-id-type="pmid">28578607</pub-id>
 </mixed-citation>
</ref>
